GlassScriptPhysician profile
Bailey Alexis Willows
NPI 1679223291
$2,870.67
in general payments reported to CMS, 2019-2025
29 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $767 · 2024: $831 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $506.89 | 2023-2025 | Ingrezza |
| Abbvie INC. | $310.27 | 2022-2025 | |
| Alkermes, INC. | $218.81 | 2023-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $214.71 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $186.93 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.81 | 2023-2025 | Caplyta |
| Lundbeck LLC | $163.10 | 2023-2025 | Rexulti |
| Corium, LLC | $141.36 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $140.66 | 2023-2025 | Rexulti, Abilify Maintena |
| Noven Therapeutics, LLC | $89.42 | 2023-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $75.61 | 2023-2025 | Qelbree, Qelbree |
| Validus Pharmaceuticals LLC | $72.66 | 2023-2025 | Equetro, Equetro |
| Teva Pharmaceuticals USA, INC. | $63.25 | 2023-2025 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $61.55 | 2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $48.75 | 2025 | Fanapt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $46.24 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $45.84 | 2025 | Cobenfy |
| Livanova USA, INC. | $41.20 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Teleflex LLC | $39.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.92 | 2023-2024 | Quviviq |
| Neos Therapeutics, LP | $33.44 | 2023-2024 | Adzenys Xr-Odt |
| Bayer Healthcare Pharmaceuticals INC. | $27.01 | 2022 | |
| Owp Pharmaceuticals, INC. | $21.17 | 2023 | Lamotrigine, Subvenite |
| Eisai INC. | $20.91 | 2024 | |
| Genzyme Corporation | $20.63 | 2022 | |
| Mission Pharmacal Company | $20.10 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.46 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.35 | 2024 | |
| Biogen, INC. | $14.68 | 2024 | Vumerity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Willows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.